Prof. Muhammad Ali Pate, Health Minister
Nigeria receives groundbreaking twice-yearly HIV prevention injection, Lenacapavir
Nigeria has achieved a significant milestone in its HIV response with the official arrival of Lenacapavir, a long-acting injectable drug designed to prevent HIV infection.
The shipment, approved by the Coordinating Minister of Health and Social Welfare, Professor Ali Pate, and supported by the Global Fund, bolsters the country’s arsenal of innovative prevention strategies.
Lenacapavir serves as pre-exposure prophylaxis (PrEP), offering a convenient alternative to daily oral pills. Administered just twice a year, it provides sustained protection for individuals at risk, a move health experts believe could dramatically improve adherence among populations facing barriers to daily treatment.
Dr. Adebobola Bashorun, National Coordinator of the National HIV, Viral Hepatitis and STDs Control Programme (NASCP), confirmed that the delivery reflects Nigeria’s commitment to evidence-based innovation in the race to control the epidemic.
“By expanding prevention options and strengthening service delivery, we are taking decisive steps to reduce new HIV infections and improve health outcomes across the country,” Bashorun stated.
He added that NASCP, in collaboration with partners, is working to ensure the safe rollout and seamless integration of Lenacapavir into national HIV prevention programs.
“Together, Nigeria moves closer to ending HIV as a public health threat,” he said.
Under voluntary licensing agreements with generic manufacturers, Lenacapavir is expected to be accessible in Nigeria and 119 other low- and middle-income countries at an affordable annual cost of $40 per person.
